Insider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $166,096.98 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton sold 18,333 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.06, for a total value of $166,096.98. Following the completion of the transaction, the chief executive officer now owns 877,608 shares of the company’s stock, valued at approximately $7,951,128.48. This trade represents a 2.05 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Mineralys Therapeutics Trading Down 2.7 %

MLYS stock opened at $9.24 on Friday. Mineralys Therapeutics, Inc. has a 12 month low of $7.95 and a 12 month high of $16.91. The stock has a market cap of $459.87 million, a PE ratio of -2.83 and a beta of 1.49. The company has a 50-day moving average price of $12.18 and a 200 day moving average price of $12.45.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same quarter last year, the firm posted ($0.57) earnings per share. Sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.

Hedge Funds Weigh In On Mineralys Therapeutics

Large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its position in shares of Mineralys Therapeutics by 72.5% during the second quarter. Bank of New York Mellon Corp now owns 84,762 shares of the company’s stock worth $992,000 after purchasing an additional 35,634 shares during the last quarter. Rhumbline Advisers increased its stake in Mineralys Therapeutics by 82.1% in the 2nd quarter. Rhumbline Advisers now owns 41,079 shares of the company’s stock worth $481,000 after buying an additional 18,519 shares during the period. American Century Companies Inc. increased its stake in Mineralys Therapeutics by 3.2% in the 2nd quarter. American Century Companies Inc. now owns 743,140 shares of the company’s stock worth $8,695,000 after buying an additional 23,170 shares during the period. Federated Hermes Inc. lifted its holdings in Mineralys Therapeutics by 100.0% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $140,000 after buying an additional 6,000 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Mineralys Therapeutics by 95.0% in the 2nd quarter. Renaissance Technologies LLC now owns 61,800 shares of the company’s stock valued at $723,000 after buying an additional 30,100 shares during the period. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.